Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy

Molecular pathways and targets in prostate cancer

(2015) Emma Shtivelman et al.   Oncotarget

The Prognostic Importance of Metastatic Site in Men with Metastatic Castration-resistant Prostate Cancer

(2013) Gregory R. Pond et al.   EUROPEAN UROLOGY

Distribution of metastatic sites in patients with prostate cancer: A population-based analysis

(2013) Giorgio Gandaglia et al.   PROSTATE

Atypical Metastases From Prostate Cancer: 10-Year Experience at a Single Institution

(2012) Anant H. Vinjamoori et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

International Variation in Prostate Cancer Incidence and Mortality Rates

(2012) Melissa M. Center et al.   EUROPEAN UROLOGY

Prostate-Cancer Mortality at 11 Years of Follow-up

(2012) Fritz H. Schröder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oncological outcomes of the prostate cancer patients registered in 2004: Report from the Cancer Registration Committee of the JUA

(2011) Hiroyuki Fujimoto et al.   INTERNATIONAL JOURNAL OF UROLOGY

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET

Predicting bone scan findings using sPSA in patients newly diagnosed of prostate cancer: Feasibility in Asian population

(2009) Miranda H.Y. Lai et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

When is a bone scan study appropriate in asymptomatic men diagnosed with prostate cancer?

(2008) Raj P. Pal et al.   ASIAN JOURNAL OF ANDROLOGY